Relay Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Par Value | Capital | Income/(Loss) | Deficit | Equity | |
| Balances at December 31, 2022 | 121,112,234 | $121 | $2,019,126 | $(10,420) | $(1,058,609) | $950,218 |
| Issuance of common stock upon milestone achievement | 1,797,064 | 2 | 12,748 | — | — | 12,750 |
| Issuance of common stock via at-the-market offerings, net | 3,026,072 | 3 | 30,278 | — | — | 30,281 |
| Issuance of common stock through exercise of stock options | 399,498 | 1 | 1,985 | — | — | 1,986 |
| Issuance of common stock via employee stock purchase plan | 244,125 | — | 2,486 | — | — | 2,486 |
| Vesting of restricted stock units | 883,416 | — | — | — | — | — |
| Stock compensation expense | — | — | 86,031 | — | — | 86,031 |
| Unrealized gain on investments | — | — | — | 10,224 | — | 10,224 |
| Net loss | — | — | — | — | (341,973) | (341,973) |
| Balance at December 31, 2023 | 127,462,409 | $127 | $2,152,654 | $(196) | $(1,400,582) | $752,003 |
| Issuance of common stock through Private Placement, net | 2,500,000 | 3 | 29,800 | — | — | 29,803 |
| Issuance of common stock via at-the-market offerings, net | 1,889,597 | 2 | 17,930 | — | — | 17,932 |
| Issuance of common stock through follow-on offering, net | 32,857,143 | 33 | 218,124 | — | — | 218,157 |
| Issuance of common stock through exercise of stock options | 617,570 | 2 | 2,780 | — | — | 2,782 |
| Issuance of common stock via employee stock purchase plan | 303,670 | 1 | 1,478 | — | — | 1,479 |
| Vesting of restricted stock units | 2,125,326 | — | — | — | — | — |
| Stock compensation expense | — | — | 94,139 | — | — | 94,139 |
| Unrealized loss on investments | — | — | — | (795) | — | (795) |
| Net loss | — | — | — | — | (337,708) | (337,708) |
| Balances at December 31, 2024 | 167,755,715 | $168 | $2,516,905 | $(991) | $(1,738,290) | $777,792 |
| Issuance of common stock through exercise of stock options | 111,209 | — | 524 | — | — | 524 |
| Issuance of common stock via employee stock purchase plan | 364,846 | — | 1,080 | — | — | 1,080 |
| Vesting of restricted stock units | 5,637,179 | — | — | — | — | — |
| Stock compensation expense | — | — | 62,419 | — | — | 62,419 |
| Unrealized gain on investments | — | — | — | 1,724 | — | 1,724 |
| Net loss | — | — | — | — | (276,479) | (276,479) |
| Balances at December 31, 2025 | 173,868,949 | $168 | $2,580,928 | $733 | $(2,014,769) | $567,060 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.